Menu
Search
|

Menu

Close
X

Amgen Inc AMGN.OQ (NASDAQ Stock Exchange Global Select Market)

189.84 USD
-1.92 (-1.00%)
As of 5:11 PM BST
chart
Previous Close 191.76
Open 191.48
Volume 428,574
3m Avg Volume 1,503,978
Today’s High 191.48
Today’s Low 189.80
52 Week High 201.23
52 Week Low 163.31
Shares Outstanding (mil) 729.67
Market Capitalization (mil) 135,588.20
Forward P/E 16.90
Dividend (Yield %) 1.15 ( 2.48 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.30 Mean rating from 23 analysts

KEY STATS

Revenue (mm, USD)
FY18
5,554
FY17
22,849
FY16
22,991
FY15
21,662
EPS (USD)
FY18
3.356
FY17
10.999
FY16
10.260
FY15
9.060
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
16.90
32.76
Price to Sales (TTM)
vs sector
5.88
5.73
Price to Book (MRQ)
vs sector
4.28
5.47
Price to Cash Flow (TTM)
vs sector
13.19
23.29
Total Debt to Equity (MRQ)
vs sector
110.53
16.84
LT Debt to Equity (MRQ)
vs sector
105.93
12.51
Return on Investment (TTM)
vs sector
11.98
14.61
Return on Equity (TTM)
vs sector
26.43
16.34

EXECUTIVE LEADERSHIP

Robert Bradway
Chairman of the Board, President, Chief Executive Officer, Since 2013
Salary: $1,555,960.00
Bonus: --
David Meline
Executive Vice President, Chief Financial Officer, Since 2014
Salary: $970,769.00
Bonus: --
Sean Harper
Executive Vice President - Research and Development, Since 2012
Salary: $970,769.00
Bonus: --
Anthony Hooper
Executive Vice President - Global Commercial Operations, Since 2011
Salary: $1,050,170.00
Bonus: --
Esteban Santos
Executive Vice President, Operations, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

1 Amgen Center Dr
THOUSAND OAKS   CA   91320-1730

Phone: +1805.4471000

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

SPONSORED STORIES